Journal Article

DZNE-2025-00448

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Prospective Multicenter Evaluation of the MDS 'Suggestive of PSP' Diagnostic Criteria.

Quattrone, A.Extern* ; Franzmeier, N. ; Levin, J.DZNE* ; Petzold, G. C.DZNE* ; Spottke, A.DZNE* ; Brosseron, F.DZNE* ; Falkenburger, B.DZNE* ; Prudlo, J.DZNE* ; Gasser, T.DZNE* ; DESCRIBE-PSP Group, T. P. G. (Collaboration Author) ; Höglinger, G. U. (Last author)DZNE* ; Petzold, G. C. (Contributor)Extern* ; Kimmich, O. (Contributor)Extern* ; Falkenburger, B. (Contributor)Extern* ; Dinter, E. (Contributor)Extern* ; Höglinger, G. (Contributor)Extern* ; Palleis, C. (Contributor)Extern* ; Bernhardt, A. M. (Contributor)Extern* ; Levin, J. (Contributor)Extern* ; Katzdobler, S. (Contributor)Extern* ; Jäck, A. (Contributor)Extern* ; Prudlo, J. (Contributor)Extern* ; Gasser, T. (Contributor)Extern* ; Brockmann, K. (Contributor)Extern* ; Spottke, A. (Contributor)Extern* ; Gamez, A. (Contributor)Extern* ; Brosseron, F. (Contributor)Extern* ; Klietz, M. (Contributor) ; Wegner, F. (Contributor) ; Pötter-Nerger, M. (Contributor) ; Pedrosa, D. J. (Contributor) ; Eggers, C. (Contributor) ; Mollenhauer, B. (Contributor)Extern* ; Claus, I. (Contributor) ; Regensburger, M. (Contributor) ; Süß, P. (Contributor) ; Warnecke, T. (Contributor) ; Gandor, F. (Contributor) ; Gruber, D. (Contributor) ; Berg, D. (Contributor) ; Paschen, S. (Contributor) ; Claßen, J. (Contributor) ; Kassubek, J. (Contributor)Extern* ; Jost, W. H. (Contributor) ; Tönges, L. (Contributor)

2025
Wiley New York, NY

This record in other databases:    

Please use a persistent id in citations: doi:10.1002/mds.30112

Abstract: The recent Movement Disorders Society (MDS)-progressive supranuclear palsy (PSP) diagnostic criteria conceptualized three clinical diagnostic certainty levels: 'suggestive of PSP' for sensitive early diagnosis based on subtle clinical signs, 'possible PSP' balancing sensitivity and specificity, and 'probable PSP' highly specific for PSP pathology.The aim of this study was to prospectively validate the criteria against long-term clinical follow-up and characterize the diagnostic certainty increase over time.Patients with 'possible PSP' or 'suggestive of PSP' diagnosis and clinical follow-up were recruited in two German multicenter longitudinal observational studies (ProPSP and DescribePSP). The cumulative percentage of patients longitudinally increasing diagnostic certainty was assessed over up to 2.5 years of follow-up. The sample size per arm required to detect 30% attenuated rate in diagnostic certainty increase in trials was estimated over multiple time intervals.Of 254 patients with available longitudinal data, 61 patients had low diagnostic certainty at baseline (48 suggestive of PSP, 13 possible PSP) and multiple clinical visits (median: 3, range: 2-4). The cumulative percentage of patients increasing diagnostic certainty progressed with follow-up duration (30.4% at 6 months, 51.7% at 1 year, 80.4% at 2.5 years). The sample size required to detect 30% reduction in diagnostic certainty increase rate within 1 year was 163, slightly smaller than that required using the PSP rating scale.Most 'suggestive of PSP' patients increased diagnostic certainty upon longitudinal follow-up, providing the first prospective multicenter validation of MDS-PSP diagnostic criteria. Our data support the design of trials tailored for these early-stage patients, suggesting the PSP rating scale and the diagnostic certainty increase rate as potential endpoint measures. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Keyword(s): Humans (MeSH) ; Supranuclear Palsy, Progressive: diagnosis (MeSH) ; Female (MeSH) ; Male (MeSH) ; Aged (MeSH) ; Middle Aged (MeSH) ; Longitudinal Studies (MeSH) ; Prospective Studies (MeSH) ; Sensitivity and Specificity (MeSH) ; Aged, 80 and over (MeSH) ; diagnostic criteria ; longitudinal ; progressive supranuclear palsy ; suggestive of PSP ; validation

---

Contributing Institute(s):

1. Clinical Research (Munich) (Clinical Research (Munich))
2. Clinical Neurodegeneration (AG Levin)
3. Vascular Neurology (AG Petzold)
4. Clinical Research Platform (CRP) (AG Spottke)
5. Neuroinflammation, Biomarker (AG Heneka)
6. Translational Parkinson Research (AG Falkenburger)
7. Clinical Dementia Research (Rostock /Greifswald) (AG Teipel)
8. Parkinson Genetics (AG Gasser)

Research Program(s):

1. 353 - Clinical and Health Care Research (POF4-353) (POF4-353)

Experiment(s):

1. DZNE Clinical Registry Study of Neurodegenerative Diseases in Patients with Progressive Supranuclear Paresis (PSP)

Appears in the scientific report 2025

---

Database coverage:
; ; ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Current Contents - Life Sciences ; DEAL Wiley ; Ebsco Academic Search ; Essential Science Indicators ; IF >= 5 ; JCR ; Nationallizenz ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---